Low-molecular-weight heparin (fragmin) and thrombin active-site inhibitor (argatroban) compared in experimental arterial and venous thrombosis and bleeding time

Journal of Cardiovascular Pharmacology

Volumn 28, Issue 1, 1996, Pages 19-25

  Schumacher, William A ^a   Heran, Christopher L ^a   Steinbacher, Thomas E ^a  

^a BRISTOL MYERS SQUIBB   (United States)

Author keywords

Anticoagulant; Argatroban; Bleeding time; Fragmin; Rats; Thrombin inhibition; Thrombosis

Indexed keywords

ARGATROBAN; DALTEPARIN; LOW MOLECULAR WEIGHT HEPARIN; MEMBRANE RECEPTOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTICOAGULATION; ARTERY THROMBOSIS; ARTICLE; BLEEDING TIME; CONTROLLED STUDY; DRUG EFFICACY; ENZYME ACTIVE SITE; ENZYME INACTIVATION; ENZYME INHIBITION; HEMOSTASIS; NONHUMAN; PARTIAL THROMBOPLASTIN TIME; PRIORITY JOURNAL; RAT; THROMBOCYTE AGGREGATION; VEIN THROMBOSIS;

ANIMALS; ANTITHROMBINS; BLEEDING TIME; DALTEPARIN; DOSE-RESPONSE RELATIONSHIP, DRUG; FIBRINOLYTIC AGENTS; MALE; PARTIAL THROMBOPLASTIN TIME; PIPECOLIC ACIDS; RATS; RATS, SPRAGUE-DAWLEY; THROMBOSIS;

EID: 0029952487     PISSN: 01602446     EISSN: None     Source Type: Journal    
DOI: 10.1097/00005344-199607000-00004     Document Type: Article

References (26)

1. Bush LR. Argatroban, a selective, potent thrombin inhibitor. Cardiovasc Drug Rev 1992;9:247-63.
2. Green D, Hirsh J, Heit J, Prins M, Davidson B, Lensing AWA. Low molecular weight heparin: a critical analysis of clinical trials. Pharmacol Rev 1994;46:89-109.
3. Vogel GMT, Meuleman DG, Bourgondiën FGM, Hobbelen PMJ. Comparison of two experimental thrombosis models in rats, effects of four glycosaminoglycans. Thromb Res 1989;54:399-410.
4. Butler KD, Ambler J, Dolan S, Giddings J, Talbot MD, Wallis RB. A nonocclusive model of arterial thrombus formation in the rat and its modification by inhibitors of platelet function, or thrombin activity. Blood Coag Fibrinolysis 1992;3:155-65.
5. Morishita K, Wada M, Kumada T, Tanaka T, Tomikawa M, Iwamoto M, Effect of ticlopidine and other antithrombotics on the venous thrombosis induced by endothelial damage of jugular veins in rats. Thromb Res 1991;63:373-84.
6. Berry CN, Girard D, Lochot S, Lecoffre C. Antithrombotic actions of argatroban in rat models of venous, 'mixed' and arterial thrombosis, and its effect on the tail transection bleeding time. Br J Pharmacol 1994;113:1209-14.
7. Schumacher WA, Steinbacher TE, Heran CL, Seiler SE, Michel I, Ogletree ML. Comparison of thrombin active-site and exosite inhibitors and heparin in experimental models of arterial and venous thrombosis and bleeding. J Pharmacol Exp Ther 1993;267:1237-42.
8. Schumacher WA, Heran CL, Steinbacher TE, Youssef S, Ogletree ML. Superior activity of a thromboxane receptor antagonist compared to aspirin in experimental arterial and venous thrombosis. J Cardiovasc Pharmacol 1993;22:526-33.
9. Kaiser B, Kühnemuth G, Markwardt F. Pharmacological studies on the low molecular weight heparin derivative CY216. Pharmazie 1990;45:522-4.
10. Cadroy Y, Harker LA, Hanson SR. Inhibition of platelet-dependent thrombosis by low molecular weight heparin (CY222): comparison with standard heparin. J Lab Clin Med 1989;114:349-57.
11. Heras M, Chesebro JH, Webster MWI, Mruk JS, Grill DE, Fuster V. Antithrombotic efficacy of low-molecular-weight heparin in deep arterial injury. Arterioscler Thromb 1992;12:250-5.
12. Eidt JF, Allison P, Nobel S, et al. Thrombin is an important mediator of platelet aggregation in stenosed canine coronary arteries with endothelial injury. J Clin Invest 1989;84:18-27.
13. 2 in reocclusion following coronary thrombolysis with tissue plasminogen activator. Proc Natl Acad Sci USA 1989;86:7585-9.
14. Mellott MJ, Connolly TM, York SJ, Bush LR. Prevention of reocclusion by MCI-9038, a thrombin inhibitor, following tPA-induced thrombolysis in a canine model of femoral arterial thrombosis. Thromb Haemostas 1991;64:526-34.
15. Jang IK, Gold HK, Ziskind AA, Leinbach RC, Fallon JT, Collen D. Prevention of platelet-rich arterial thrombosis by selective thrombin inhibition. Circulation 1990;81:219-25.
16. Thomas DP, Merton RE, Gray E, Barrowcliffe TW. The relative antithrombotic effectiveness of heparin, a low molecular weight heparin, and a pentasaccharide fragment in an animal model. Thromb Haemost 1989;61:204-7.
17. Ockelford PA, Carter CJ, Mitchel L, Hirsh J. Discordance between the anti-Xa activity and antithrombotic activity of an ultra-low molecular weight heparin fraction. Thromb Res 1982;28:401-9.
18. Ofosu FA, Blajchman MA, Modi GJ, Smith LM, Buchanan MR, Hirsh J. The importance of thrombin inhibition for the expression of the anticoagulant activities of heparin, dermatan sulphate, low molecular weight heparin and pentosan polysulphate. Br J Haematol 1985;60:695-704.
19. Amar J, Caranobe C, Sié Bonue P, Bonue B. Antithrombotic potencies of heparins in relation to their antifactor Xa and antithrombin activities: an experimental study in two models of thrombosis in the rabbit. Br J Haematol 1990;76:94-100.
20. Carrie D, Caranobe C, Saivin S, et al. Pharmacokinetic and antithrombotic properties of two pentasaccharides with high affinity to antithrombin III in the rabbit: comparison with CY216. Blood 1994;84:2571-7.
21. Berry CN, Giardot C, Lecoffre C, Lunven C. Effects of the synthetic thrombin inhibitor argatroban on fibrin- or clot-incorporated thrombin: comparison with heparin and recombinant hirudin. Thromb Haemost 1994;72:381-6.
22. Imura Y, Stassen J-M, Collen D. Comparative antithrombotic effects of heparin, recombinant hirudin and argatroban in a hamster femoral vein platelet-rich mural thrombosis model. J Pharmacol Exp Ther 1992;261:895-8.
23. Andriuoli G, Mastacchi R, Barbanti M, Sarret M. Comparison of the antithrombotic and haemorrhagic effects of heparin and a new low molecular weight heparin in rats. Haemostasis 1985;15:325-30.
24. Ljungberg B, Johnsson H. In vivo effects of a low molecular weight heparin fragment on platelet aggregation and platelet dependent hemostasis in dogs. Thromb Haemost 1988;60:232-5.
25. Bang CJ, Berstad A, Talstad I. Haemorrhagic effects of unfractionated and two low molecular weight heparins, enoxaparin and fragmin, in rats. Haemostasis 1991;21:30-6.
26. Racanelli A, Farced J. Ex vivo activity of heparin is not predictive of blood loss after neutralization by protamine. Thromb Res 1992;67:263-73.